Adversarial Batch Representation Augmentation for Batch Correction in High-Content Cellular Screening
New adversarial method actively synthesizes worst-case batch perturbations to train more robust AI models for cellular analysis.
A research team led by Lei Tong has published a new AI method called Adversarial Batch Representation Augmentation (ABRA) that tackles a critical problem in biomedical AI: batch effects in high-content cellular screening. When labs analyze millions of cell painting images to profile drug effects, technical variations between experiments create "bio-batch" effects that degrade AI model performance on new data. ABRA reframes this as a Domain Generalization problem, actively generating adversarial perturbations during training to make models robust to these unseen variations.
Unlike traditional methods that rely on prior knowledge or struggle with generalization, ABRA parameterizes feature statistics as structured uncertainties and uses a min-max optimization framework. It synthesizes worst-case bio-batch perturbations in the representation space while maintaining a strict angular geometric margin to preserve the fine-grained differences between cell phenotypes. To prevent representation collapse during this adversarial exploration, the team introduced a synergistic distribution alignment objective that keeps the learned features meaningful and discriminative.
The method was rigorously tested on two major benchmarks: the large-scale RxRx1 dataset and its more challenging variant, RxRx1-WILDS. Results show ABRA establishes a new state-of-the-art for siRNA perturbation classification, significantly outperforming previous approaches. This means AI models trained with ABRA can more accurately identify how genetic perturbations affect cells, even when analyzing data from different laboratories, equipment, or experimental conditions where batch effects would normally cause performance drops.
This advancement has immediate implications for drug discovery pipelines, where reliable phenotypic analysis across diverse experimental setups is crucial. By making deep learning models more generalizable and less susceptible to technical artifacts, ABRA could accelerate the identification of promising drug candidates and reduce false positives in high-throughput screening campaigns that rely on computer vision for cellular analysis.
- ABRA frames batch correction as Domain Generalization, using adversarial training to synthesize worst-case perturbations in feature space
- Method maintains angular geometric margin to preserve class discriminability while introducing a distribution alignment objective to prevent collapse
- Achieves state-of-the-art performance on RxRx1 and RxRx1-WILDS benchmarks for siRNA perturbation classification
Why It Matters
Enables more reliable AI models for drug discovery that work consistently across different labs and experimental conditions, reducing false results.